Cohorts A2 (single agent high dose in adjuvant setting) and B1 (low dose added to anti-PD-1) have been opened and first patient of cohort A2 has been dosed
Liège, Belgium and Grenoble, France...
We are very pleased to announce that PDC*line Pharma is one of the three nominees for the 2020 BVA Award Venture company of the year!
THE BELGIAN VENTURE CAPITAL & PRIVATE EQUITY ASSOCIATION...
PDC*line Pharma strengthens its board of directors with an
industry leader in the field of immuno-oncology
Liège, Belgium and Grenoble, France, June 25, 2020 – PDC*line Pharma, a clinical stage...
PDC*line Pharma is pleased to announce that Eric Halioua, PDC*line Pharm’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a virtual event, will be held...
We are very pleased to announce the publication in OncoImmunology of the results of the first in-human trial with our innovative plasmacytoid dendritic cell line based cancer vaccine in melanoma...
New article and interview of our President & CEO Eric Halioua for the 2020 edition of the Belgium Healthcare & Life Science Review of the magazine PharmaBoardroom. He introduces the Belgian immuno...
Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today...
Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces...
The PDC*line Pharma management team will be present in full force in San Francisco during the JP Morgan Conference 2020! Meet our President & CEO Eric Halioua and our COO Laurent Levy from Sunday Jan...
Today, a new article has been published in the newspaper l'Echos with an interview of our President & CEO Eric Halioua .The article underlines the achievements made by PDC*line Pharma over the last 4...
